FDA Modernizes Framework for Software-Based Mental Health Treatments

The U.S. Food and Drug Administration released draft guidance in September 2023 that updates how software products claiming to treat mental health conditions are classified and reviewed. This step clarifies expectations for companies developing digital therapeutics for psychiatric disorders. The changes aim to balance innovation with requirements for safety and effectiveness data.

What this means

The guidance outlines when a software tool qualifies as a medical device and what evidence developers must supply before marketing. It also signals that the agency intends to evaluate these products on a case-by-case basis while inviting public input on the draft.

Key takeaways

• The FDA issued draft guidance in September 2023 on digital health technologies for remote data acquisition that applies to mental health software. [1]
• Earlier 2022 guidance documents define how device software functions are classified and what clinical evidence is needed for products addressing diagnosed conditions. [2]
• Developers must supply data from valid clinical studies plus usability testing tailored to mental health users. [3]
• The documents remain in draft form and products continue to be assessed individually rather than under a single blanket rule.
• Public comments are being accepted as part of the process to refine the final expectations.

Main Components and Criteria

The September 2023 draft focuses on premarket submission requirements and clinical evidence expectations for software as a medical device that targets mental health. It describes documentation needed to show that a product can safely and effectively address psychiatric disorders. Patient engagement standards also appear in the text.

How does classification work under these rules? The FDA determines device status based on the intended use and the risks tied to the claimed treatment effect.

Impact on Regulatory Pathway

The 2022 policy document explains when software functions fall under FDA oversight versus when they remain outside regulation. This creates a more defined route for firms that want to market tools for diagnosed mental health conditions. Developers now have clearer markers for when a submission is required.

Even so, the pathway still requires case-specific review rather than automatic clearance.

Required Standards and Evidence

Clinical evaluation guidance from 2022 stresses that sponsors provide evidence from controlled studies plus human factors validation. Testing must reflect the populations that would use the product for mental health purposes. The agency expects both safety and effectiveness data before any marketing authorization.

What happens next depends on comments received during the open period and any revisions that follow.

Limitations

The FDA's recent guidance documents are draft versions. Final requirements may change after public consultation. The documents themselves do not create binding rules, and each product is evaluated on its own merits.

This article draws from public FDA sources and supplies general information only. It is not a substitute for personalized medical guidance.

Last updated: September 2, 2026